Hepatitis C virus (HCV) infection is a systemic disease associated with both hepatic and extrahepatic manifestations. The burden associated with the hepatic manifestation of HCV infection has been well documented in Europe, although that of HCV extrahepatic manifestations remains unknown. In this study, we estimated the annual direct medical costs associated with HCV extrahepatic manifestations in five European countries. A previously validated economic model was used to estimate the annual direct medical cost associated with HCV extrahepatic manifestations.
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Summary
Hepatitis C virus (HCV) infection is a systemic disease associated with both hepatic and extrahepatic manifestations. The burden associated with the hepatic manifestation of HCV infection has been well documented in Europe, although that of HCV extrahepatic manifestations remains unknown. In this study, we estimated the annual direct medical costs associated with HCV extrahepatic manifestations in five European countries. A previously validated economic model was used to estimate the annual direct medical cost associated with HCV extrahepatic manifestations.
Global excess prevalence of extrahepatic manifestations in HCV patients relative to that in non-HCV patients was obtained from a recent meta-analysis. Per-patient peryear inpatient, outpatient and medication costs to treat each extrahepatic manifestation were from the literature, national databases or expert opinion if unavailable otherwise. All costs were adjusted to 2016 euros (€). The overall direct medical costs associated with HCV extrahepatic manifestations were calculated by multiplying the total per-patient per-year costs of each by the respective excess prevalence rates and then by the size of the HCV-infected population in each country. Treatment impact with direct-acting antivirals (DAAs) was explored using HCV extrahepatic manifestations excess prevalence rates among cured patients compared to untreated HCV patients, as sourced from a meta-analysis. The total annual direct medical cost associated with HCV extrahepatic manifestations was estimated to be 2.17 billion euro (€), with a per-HCV-patient cost ranging from €899 to €1647 annually. DAA treatment was projected to result in cost savings of €316 million per year. We find that the annual economic burden of extrahepatic manifestations is significant and may be partly mitigated by treatment with DAAs.
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| INTRODUC TI ON
Hepatitis C virus (HCV) infection is a systemic disease which is associated with both hepatic and extrahepatic manifestations (EHM). In Europe, over 19 million persons are infected with HCV. 1 The clinical and economic consequences of the hepatic manifestations of HCV are well characterized. These can include progression to cirrhosis, decompensation, hepatocellular carcinoma and liver transplant, significantly impacting patient morbidity and mortality and contributing substantially to the economic burden of disease.
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In addition to the hepatic burden of disease, it has been shown that up to 74% of HCV patients may experience EHMs. 3 A systematic review identified more than 200 studies documenting the association of various EHMs with HCV. 4 A recent meta-analysis has further quantified the excess prevalence of specific EHMs, including type 2 diabetes, B-cell lymphoma and Sjögren's syndrome, in HCV patients. 5 Prior work has shown that the annual economic burden of EHMs of HCV is substantial in the USA and France, at $1.5 billion (bn) and €256 million (m), respectively. 5, 6 However, the direct medical costs associated with HCV-related EHMs in other European countries remain unknown.
The current standard of care for HCV involves treatment with direct-acting antivirals (DAAs). 7 DAAs have shown excellent safety and tolerability in HCV patients of all genotypes, with sustained virologic response (SVR) rates in excess of 95% in most subpopulations 8, 9 and significant improvements on patient-reported outcomes. 10, 11 There are a large number of studies that document the significant morbidity and mortality benefit of achieving SVR in HCV patients at all stages of fibrosis. 4 Thus, early treatment with DAAs can prevent a substantial portion of direct medical costs related to downstream hepatic HCV complications. [12] [13] [14] [15] [16] [17] [18] Treatment of at-risk populations with DAAs has also been projected to reduce viral transmission. 19, 20 Achieving SVR can also lessen the clinical burden of EHMs. 
| MATERIAL S AND ME THODS
A previously validated economic analysis 5 was adapted to the German, Spanish, Italian, and UK perspectives and used to estimate the annual direct medical cost associated with EHMs of HCV.
Estimates from the French perspective were taken from our previously published analyses. 6 Global excess prevalence of the 13 most commonly known EHMs The overall national direct medical annual costs associated with each EHM were calculated by multiplying the total PPPY costs of each condition by its respective excessive prevalence rate (Table 1) and then by the size of the HCV-infected population in each country, which was sourced from the literature (Table S1 ).
The impact of DAA treatment and achievement of SVR on the economic burden of EHMs were evaluated by applying the results of a meta-analysis assessing the reduction in EHM prevalence in patients achieving SVR to the calculated healthcare costs of managing each EHM. 6 Briefly, this meta-analysis estimated the total cost reduction according to SVR for the five major EHMs for which data are available in the literature exists (mixed cryoglobulinemia vasculitis, end-stage renal disease, T2DM, stroke and myocardial infarction [21] [22] [23] [24] [25] ) and weighted the results according to the size of the study population. In our analysis, we assumed that all patients receiving DAA treatment would be cured, resulting in a relative reduction in excess prevalence for these EHMs.
Sensitivity analysis was performed by considering the 95% confidence intervals for the EHM prevalence rates as reported in the meta-analysis, which was descriptive in nature in that no formal statistical analyses were performed.
| RE SULTS
The literature review revealed a wide variability in country-specific per-patient costs for managing each EHM ( Table 1 ). The range of cross-country variability in annual per-patient management costs of each EHM ranged from 500 EUR (porphyria cutanea tarda) to 43 594 EUR (lymphoma). EHMs with the largest relative variability of annual per-patient costs across countries included arthritis, lymphoma, glomerulonephritis and depression (Table 1) .
Applying the excess prevalence rates of EHMs from the international meta-analysis to country-specific 2016 healthcare costs, we estimated the total annual economic burden of EHMs of HCV in the EU5 to be €2.17 billion (bn), as detailed in Table 2 . Annual total medical costs were highest in Italy and lowest in the UK. Sensitivity analyses based on the 95% confidence intervals of the excess EHM prevalence rates from the meta-analysis projected the direct medical costs associated with HCV-EHMs to range from a low of €121 m in the UK to a high of €1490 m in ITA and are detailed in Table 2 .
The proportional contribution of each EHM to the projected burden of disease is detailed in Table S2 ; the EHMs that contributed most to €534, €128 to €270 and €32 to €249, respectively, depending on the country.
TA B L E 1 Prevalence rates and per-patient per-year costs associated with extrahepatic manifestations of HCV infection, by country
Based on the assumption that all HCV patients receiving DAA treatment would be cured, the total reduction in direct medical costs of managing EHMs attributable to patients achieving SVR varied by country, with annual estimates of cost savings ranging from €22.9 m in the UK to €145.1 m in Italy (Table 3) . This corresponded to relative savings of 11.3%-18.7%, depending on the country.
| D ISCUSS I ON
Our study estimates that the annual economic burden of extrahepatic manifestations in the EU5 is substantial, adding significantly to the overall burden of HCV infection. Further, we find that treatment with DAAs may lead to a reduction in this burden.
Our study's projections are in line with prior work assessing the economic burden of EHMs in the USA, which has been estimated at $1.5 billion annually. 5 In our study, the magnitude of the annual eco- Our study is one of only a few to simulate the impact of DAA treatment on the economic burden of EHMs. 6 The EHMs with the greatest contributions to estimated cost savings upon achievement of SVR were T2DM and mixed cryoglobulinemia, given their high rate of excess prevalence in HCV patients and substantial per-patient costs. Our projections of SVR leading to decreased direct medical costs for particular EHMs were consistent with realworld findings: a study at a tertiary centre in France has shown that when HCV patients with mixed cryoglobulinemia are treated with DAAs, direct medical costs due to hospitalization and non-HCV pharmacy prescriptions decrease, reflecting the lesser need for medical management of this EHM after a patient is cured of HCV.
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There is a lack of clear evidence on whether DAA treatment reduces the excess prevalence and/or severity of all EHMs; in our anal- Our study is not without limitations. Excess prevalence rates were sourced from a meta-analysis that included both primary care and specialist clinic data. As a result, these rates may be an overestimation of the excess prevalence in the general HCV population; to address this limitation, our sensitivity analyses explored the potential impact of lower EHM excess prevalence rates on the economic burden of disease, which remained substantial.
The EHM prevalence rates used in our analysis were international, not country-specific, and sourced from a meta-analysis that aggregated prevalence rates across different years; further research should seek to understand country-specific EHM prevalence.
The costs of managing each EHM were not directly available in all countries, and the approximations of resource utilization (eg using hospitalization length-of-stay data from Spain to approximate these data for Italian and German patients) based on expert opinion that we used in our analysis may be subject to bias. Our analysis did not explicitly account for any double-counting of particular costs in patients who may have more than one related EHM (ie both myocardial infarction and T2DM). Finally, our analysis did not stratify EHM costs based on treatment experience, cirrhosis status or EHM severity, or account for HCV patients that have already been cured by DAAs; further research is warranted to understand the impact of each of these parameters on the overall burden of disease.
In summary, we show that the economic burden associated with the extrahepatic manifestations of HCV in Europe is substantial and that treatment with DAAs can reduce a considerable portion of these direct medical costs.
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